Eisai Announces Publication of Post Hoc Analysis Data of LENVIMA® (lenvatinib) from Phase 3 SELECT Trial in Certain Patients with Differentiated Thyroid Cancer in the European Journal of Cancer
News provided by
Share this article
published the results from a post hoc analysis of the Phase 3 SELECT study evaluating the impact of lung metastases on overall survival (OS) in patients with locally recurrent or metastatic, progressive radioiodine-refractory differentiated thyroid cancer (RAI-refractory DTC) who were treated with LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. These data were originally presented at the European Society for Medical Oncology (ESMO) Annual Meeting in September 2019.
Helsinn appoints Mary Lynne Hedley to Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Eisai Announces Publication of Post Hoc Analysis Data of LENVIMA® (lenvatinib) from Phase 3 SELECT Trial in Certain Patients with Differentiated Thyroid Cancer in the European Journal of Cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
It was August of 2013, and 33-year-old Nefa-Tari Moore had been having a pretty good year. She was working as a licensed practical nurse (LPN) in Brooklyn, NY, and had just gotten married in July. When she started experiencing heavy vaginal bleeding and lower back pain, Moore didn’t think much of it at first until one day in November when her pain really escalated. “That morning, I was too weak to get out of bed,” she recalls. “That’s when I decided to [hop in a cab and] go to the emergency room.”
But even at the hospital, she knew the answers she was getting didn’t tell the full story. “I was told by the doctors that the bleeding may just be a change of menstrual cycles, me being stressed, or that it was all in my head,” Moore says. “They wanted to give me ibuprofen and recommended that I go home and rest.” But she insisted on staying for further observation. Thanks to her persistence, the ER staff set her up with an OB/GYN referral, which ultimately led to t